Statin therapy in stroke prevention: a meta-analysis involving 121,000 patients.

[1]  Yasuo Ohashi,et al.  Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): a prospective randomised controlled trial , 2006, The Lancet.

[2]  M. Hennerici,et al.  High-dose atorvastatin after stroke or transient ischemic attack. , 2006, The New England journal of medicine.

[3]  H. Shimomura,et al.  Effects of early statin treatment on symptomatic heart failure and ischemic events after acute myocardial infarction in Japanese. , 2006, The American journal of cardiology.

[4]  P. Wolf,et al.  Heart disease and stroke statistics--2006 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. , 2006, Circulation.

[5]  E. Rahme,et al.  Are statins created equal? Evidence from randomized trials of pravastatin, simvastatin, and atorvastatin for cardiovascular disease prevention. , 2006, American heart journal.

[6]  Paula Finn,et al.  American Heart Association--scientific sessions 2005. 13-16 November 2005, Dallas, TX, USA. , 2006, IDrugs : the investigational drugs journal.

[7]  Matthew A Silva,et al.  Statin-related adverse events: a meta-analysis. , 2006, Clinical therapeutics.

[8]  N. Coplan,et al.  The role of statins in preventing stroke. , 2005, Preventive cardiology.

[9]  M. Briel,et al.  Statin therapy for prevention and treatment of acute and chronic cardiovascular disease: update on recent trials and metaanalyses , 2005, Current opinion in lipidology.

[10]  R. Collins,et al.  Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins , 2005, The Lancet.

[11]  W. März,et al.  Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. , 2005, The New England journal of medicine.

[12]  M. Nobuyoshi,et al.  Three-year follow-up results of angiographic intervention trial using an HMG-CoA reductase inhibitor to evaluate retardation of obstructive multiple atheroma (ATHEROMA) study. , 2005, Circulation journal : official journal of the Japanese Circulation Society.

[13]  S. Hosoda,et al.  Effect of pravastatin on progression of coronary atherosclerosis in patients after coronary artery bypass surgery. , 2005, Circulation journal : official journal of the Japanese Circulation Society.

[14]  P. Stone,et al.  Effect of Intensive Lipid Lowering, With or Without Antioxidant Vitamins, Compared With Moderate Lipid Lowering on Myocardial Ischemia in Patients With Stable Coronary Artery Disease: The Vascular Basis for the Treatment of Myocardial Ischemia Study , 2005, Circulation.

[15]  M. Briel,et al.  Effect of different antilipidemic agents and diets on mortality: a systematic review. , 2005, Archives of internal medicine.

[16]  Giovanni Amoroso,et al.  Simvastatin does not inhibit intimal hyperplasia and restenosis but promotes plaque regression in normocholesterolemic patients undergoing coronary stenting: a randomized study with intravascular ultrasound. , 2005, American heart journal.

[17]  J. Sasaki,et al.  Relation of serum total cholesterol and other factors to risk of cerebral infarction in Japanese men with hypercholesterolemia. , 2004, Circulation journal : official journal of the Japanese Circulation Society.

[18]  G. Mancia,et al.  Different Effects of Antihypertensive Regimens Based on Fosinopril or Hydrochlorothiazide With or Without Lipid Lowering by Pravastatin on Progression of Asymptomatic Carotid Atherosclerosis: Principal Results of PHYLLIS—A Randomized Double-Blind Trial , 2004, Stroke.

[19]  D. Hunninghake,et al.  Clinical outcomes in managed-care patients with coronary heart disease treated aggressively in lipid-lowering disease management clinics: the alliance study. , 2004, Journal of the American College of Cardiology.

[20]  Hans L. Hillege,et al.  Effects of Fosinopril and Pravastatin on Cardiovascular Events in Subjects With Microalbuminuria , 2004, Circulation.

[21]  M. Briel,et al.  Effects of statins on stroke prevention in patients with and without coronary heart disease: A meta-analysis of randomized controlled trials , 2004 .

[22]  J. Reiber,et al.  Randomized, controlled trial of secondary prevention of coronary sclerosis in normocholesterolemic patients using pravastatin: final 5-year angiographic follow-up of the Prevention of Coronary Sclerosis (PCS) study. , 2004, International journal of cardiology.

[23]  John H Fuller,et al.  Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial , 2004, The Lancet.

[24]  M. Hennerici,et al.  Statins for Secondary Stroke Prevention in Patients without Known Coronary Heart Disease: The Jury Is Still Out , 2004, Cerebrovascular Diseases.

[25]  M. Yacoub,et al.  Efficacy and safety of fluvastatin therapy for hypercholesterolemia after heart transplantation: results of a randomised double blind placebo controlled study. , 2004, International journal of cardiology.

[26]  R. Collins,et al.  Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20 536 people with cerebrovascular disease or other high-risk conditions , 2004, The Lancet.

[27]  J. Slattery,et al.  Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). 1994. , 1994, Atherosclerosis. Supplements.

[28]  Mark A. Creager,et al.  Cholesterol Reduction With Atorvastatin Improves Walking Distance in Patients With Peripheral Arterial Disease , 2003, Circulation.

[29]  I. Holme,et al.  Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial , 2003, The Lancet.

[30]  R. Collins,et al.  Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial—Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial , 2003, The Lancet.

[31]  Douglas G Altman,et al.  Validity of indirect comparison for estimating efficacy of competing interventions: empirical evidence from published meta-analyses , 2003, BMJ : British Medical Journal.

[32]  Barry R. Davis,et al.  Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). , 2002, JAMA.

[33]  J. Tijssen,et al.  Effect of fluvastatin on ischaemia following acute myocardial infarction: a randomized trial. , 2002, European heart journal.

[34]  P. Macfarlane,et al.  Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial , 2002, The Lancet.

[35]  AndrewJ. S. Coats.  MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebocontrolled trial , 2002, The Lancet.

[36]  P. Serruys,et al.  Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: a randomized controlled trial. , 2002, JAMA.

[37]  S. Thompson,et al.  Quantifying heterogeneity in a meta‐analysis , 2002, Statistics in medicine.

[38]  S. Thompson,et al.  How should meta‐regression analyses be undertaken and interpreted? , 2002, Statistics in medicine.

[39]  V. Athyros,et al.  Treatment with Atorvastatin to the National Cholesterol Educational Program Goal Versus 'Usual' Care in Secondary Coronary Heart Disease Prevention , 2002, Current medical research and opinion.

[40]  S. Yusuf.  MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controlled trial. Commentary , 2002 .

[41]  Michael F. Oliver,et al.  Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes. The MIRACL study. , 2001, Indian heart journal.

[42]  G. Berglund,et al.  Low-Dose Metoprolol CR/XL and Fluvastatin Slow Progression of Carotid Intima-Media Thickness: Main Results From the &bgr;-Blocker Cholesterol-Lowering Asymptomatic Plaque Study (BCAPS) , 2001, Circulation.

[43]  Arthur S Slutsky,et al.  Agreement between alternative classifications of acute respiratory distress syndrome. , 2001, American journal of respiratory and critical care medicine.

[44]  K. Teo,et al.  Long-Term Effects of Cholesterol Lowering and Angiotensin-Converting Enzyme Inhibition on Coronary Atherosclerosis: The Simvastatin/Enalapril Coronary Atherosclerosis Trial (SCAT) , 2000, Circulation.

[45]  P Glasziou,et al.  Pravastatin therapy and the risk of stroke. , 2000, The New England journal of medicine.

[46]  A. Gotto,et al.  The evolving role of statins in the management of atherosclerosis. , 2000, Journal of the American College of Cardiology.

[47]  G. Guyatt,et al.  Systematic review on the risk and benefit of different cholesterol-lowering interventions. , 1999, Arteriosclerosis, thrombosis, and vascular biology.

[48]  R. Collins,et al.  Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. , 1998, The New England journal of medicine.

[49]  A. Gotto,et al.  Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. , 1998, JAMA.

[50]  G. Guyatt,et al.  Effect of HMGcoA Reductase Inhibitors on Stroke , 1998, Annals of Internal Medicine.

[51]  C. Hennekens,et al.  Cholesterol lowering with statin drugs, risk of stroke, and total mortality. An overview of randomized trials. , 1997, JAMA.

[52]  R. Westendorp,et al.  Stroke, statins, and cholesterol. A meta-analysis of randomized, placebo-controlled, double-blind trials with HMG-CoA reductase inhibitors. , 1997, Stroke.

[53]  H. Wieland,et al.  The effect of simvastatin on progression of coronary artery disease. The Multicenter coronary Intervention Study (CIS). , 1997, European heart journal.

[54]  G. Gallus,et al.  Pravastatin reduces carotid intima-media thickness progression in an asymptomatic hypercholesterolemic mediterranean population: the Carotid Atherosclerosis Italian Ultrasound Study. , 1996, The American journal of medicine.

[55]  B. Davis,et al.  The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. , 1996, The New England journal of medicine.

[56]  D. Kromhout.  Cholesterol, diastolic blood pressure, and stroke: 13 000 strokes in 450 000 people in 45 prospective cohorts , 1995, The Lancet.

[57]  P. Macfarlane,et al.  Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia , 1995 .

[58]  J. Salonen,et al.  Kuopio Atherosclerosis Prevention Study (KAPS). A population-based primary preventive trial of the effect of LDL lowering on atherosclerotic progression in carotid and femoral arteries. , 1995, Circulation.

[59]  G J Boerma,et al.  Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels. The Regression Growth Evaluation Statin Study (REGRESS). , 1995, Circulation.

[60]  C. Furberg,et al.  Effect of Cholesterol-Lowering Medications on Progression of Mild Atherosclerotic Lesions of the Carotid Arteries and on the Risk of Stroke , 1995 .

[61]  C. Furberg,et al.  Pravastatin, Lipids, and Atherosclerosis in the Carotid Arteries (PLAC-II) , 1995, The American journal of cardiology.

[62]  M-heart investigators.  Effect of simvastatin on coronary atheroma: the Multicentre Anti-Atheroma Study (MAAS) , 1994, The Lancet.

[63]  D. Waters,et al.  Effects of monotherapy with an HMG-CoA reductase inhibitor on the progression of coronary atherosclerosis as assessed by serial quantitative arteriography. The Canadian Coronary Atherosclerosis Intervention Trial. , 1994, Circulation.

[64]  Stanley Azen,et al.  Coronary Angiographic Changes with Lovastatin Therapy: The Monitored Atherosclerosis Regression Study (MARS) , 1993, Annals of Internal Medicine.

[65]  J. Fleiss.  Review papers : The statistical basis of meta-analysis , 1993 .

[66]  D. Jacobs,et al.  Serum cholesterol levels and six-year mortality from stroke in 350,977 men screened for the multiple risk factor intervention trial. , 1989, The New England journal of medicine.

[67]  N. Laird,et al.  Meta-analysis in clinical trials. , 1986, Controlled clinical trials.

[68]  P. Sheehe,et al.  Combination of log relative risk in retrospective studies of disease. , 1966, American journal of public health and the nation's health.